Journal of Infection最新文献

Background: The emergence of SARS-CoV-2 variants necessitates ongoing evaluation of vaccine performance. This study evaluates and compares the safety and immunogenicity of the Comirnaty and Spikevax monovalent XBB.1.5 COVID-19 vaccines in an elderly population.

Methods: Altogether, 129 elderly individuals were recruited between 2 January and 3 February 2024, and received a booster dose of either Comirnaty (n=59) or Spikevax (n=70) monovalent XBB.1.5 COVID-19 vaccine. Blood samples were collected at before and one month after vaccination. Immunogenicity was assessed by measuring the percentage of IFNγ⁺CD4⁺ and IFNγ⁺CD8⁺ T cells, and neutralizing antibody titers (NT50) using a surrogate virus neutralization test (sVNT). Adverse reactions were recorded and analyzed.

Findings: Both vaccines significantly increased the percentage of IFNγ⁺CD8⁺ T cells against XBB.1.5 and wild-type (WT) SARS-CoV-2 at one-month post-vaccination. Spikevax induced a significantly higher percentages of IFNγ⁺CD8⁺ and CD4⁺ T cells against XBB.1.5 than Comirnaty (p<0.001). The proportion of participants showing a positive T cell response to XBB1.5 after vaccination was higher in the Spikevax group (64.3% CD8, 71.4% CD4) than in the Comirnaty group (42.4% CD8, 57.6% CD4). Spikevax also elicited higher NT50 levels against XBB1.5, JN.1 and the latest variant KP.2 than Comirnaty (XBB1.5: p<0.01; KP.2: p<0.05). Fever was more common in the Spikevax group (fever: p=0.006). However, all side effects were short-term and resolved on their own.

Interpretation: Both vaccines induce neutralizing antibody to XBB1.5, JN.1 and KP.2. Specifically, Spikevax induces higher cellular and humoral immune responses than Comirnaty in the elderly, but it is also associated with a higher incidence of fever. These findings can guide public health strategies for vaccinating the elderly population.

Background: People who inject drugs (PWID) have high rates of bloodstream infections (BSI) with Staphylococcus aureus (SA) and group A streptococcus (GAS). Little is known about health-related quality of life outcomes after BSI.

Methods: We performed a prospective pilot cohort study of patients with BSI due to SA or GAS. Health-related quality of life, anxiety, depression and cognitive function were assessed using validated tools (EQ5-5D-5L), Hospital Anxiety and Depression Score (HADS) and Montreal Cognitive Assessment (MOCA) at baseline, 28 days post-discharge and 6 months post-infection.

Findings: 66 patients were recruited over a 12-month period, including 17 PWID. For the whole cohort, global health rank improved from baseline to day 28 (median 40 to 60, p=0.002), with no significant improvement from day 28 to day 168 (median 60 to 75, p=0.161). At baseline, PWID had lower overall health-related quality of life than non-PWID (median 25 vs 45, p=0.229), persisting at day 28 (non-PWID median 65, PWID median 43, p=0.036) and day 168 (non-PWID median 75, PWID median 40, p=0.035). This difference was driven by worse scores in the EQ-5D-5L mental health component and HADS, with HADS scores being significantly impaired in PWID at baseline (p=0.001) and day 28 (p=0.007).

Conclusion: PWID have impaired health-related quality of life after SA and GAS BSI that persists for up to 6 months. Poor mental health is the major component of this, and further studies could clarify if this is a target for intervention.

Background: Pneumococcal infections are associated with significant morbidity and mortality, especially at the extremes of age and in those with underlying conditions. Little is known about the risks, presentations or outcomes of invasive pneumococcal disease (IPD) during pregnancy or the postpartum period.

Methods: The UK Health Security Agency conducts enhanced national surveillance of IPD in England. We used national surveillance data to calculate IPD risk and outcomes in pregnant, postpartum and non-pregnant women of childbearing age with IPD over a five-year period in England.

Findings: There were 1701 IPD cases in women aged 15-44 years between 1 July 2014 and 30 June 2019, including 123 (7.2%) pregnant, 38 (2.2%) postpartum and 1540 (90.5%) non-pregnant women. IPD incidence in pregnant women (0.048/1000 woman-years) was not significantly different compared to non-pregnant women (0.041/1000 woman-years; Incidence Rate Ratio [IRR]: 1.17; 95%CI 0.96-1.40; p=0.11). When stratified by trimester, however, women in their third trimester had a 2.27-fold (95%CI 1.80-2.85, p<0.001) increased risk of IPD, compared to non-pregnant women (IRR 2.27, 95%CI 1.78-2.85, p<0.001), while those in the first (IRR 0.49, 95%CI 0.28-0.80) and second trimester (IRR 0.71, 95%CI 0.47-1.04) had a lower risk, albeit only statistically significant for the first trimester. Postpartum women (0.144 per 1000 woman-years), on the other hand, had a 3.49-fold (95%CI 2.46-4.81, p<0.001) higher IPD risk than non-pregnant women. Most pregnant women developed IPD during their third trimester (80/123, 65.0%), with all but one pregnancy resulting in a live birth. IPD in the second trimester was associated with live birth in 77.8% of cases (21/27), while 22.2% experienced a miscarriage (5/27, 18.5%) or stillbirth (1/27, 3.7%). IPD in the first trimester was associated with live birth in 41.7% of cases (5/12), miscarriages in 41.7% (5/12), and termination in 16.7% (2/12) cases. Only three neonates (3/142) had confirmed IPD. There were no deaths in pregnant women with IPD compared to 5.5% (85/1540) in non-pregnant women.

Interpretation: While pregnant women overall did not appear to have an increased risk of IPD compared to non-pregnant women, those infected in third trimester or postpartum appeared to have more than twice the incidence. Most pregnant and postpartum women had a live birth, and subsequent neonatal infection was rare, occurring in 2% of live births.

Objectives: Although the relationship between urbanization and influenza has received increasing attention, previous studies have often examined this relationship based on single indicators, neglecting the multi-dimensions of urban development and their integrated impact on influenza incidence in neighboring cities.

Methods: A multidimensional urbanization evaluation framework was developed based on social, economic, and ecological dimensions to comprehensively assess urbanization. Then, we analyzed the impact of urbanization development on influenza incidence within and across cities using Bayesian spatiotemporal models and spatial Durbin models. Regional heterogeneity analysis was performed to investigate the impact of urbanization on influenza incidence within cities.

Results: From 2014 to 2019, there were 5,062,254 influenza cases in 283 prefecture-level cities in China. Each standard deviation increment in comprehensive, social, and economic indexes of urbanization was associated with a 14.9% (95% CI: 6.1%, 24.3%), 9.9% (95% CI: 3.5%, 16.3%), and 13.4% (95% CI: 4.5%, 23.7%) increase in influenza incidence, respectively. The effects of urban development on influenza incidence varied significantly across regions, with the greatest impact found in southern China. Additionally, a significant positive spatial spillover effect of urbanization was observed on influenza incidence in surrounding cities.

Conclusions: Urbanization and its various dimensions were linked to increased risk of local influenza incidence, which also showed substantial positive spatial spillover effect to surrounding areas. During the rapid urbanization process in China, local governments should prioritize equity and accessibility in healthcare services and strengthen the coordinated prevention and control of influenza epidemics across cities.

Background: Antibiotics are the most commonly prescribed drugs during pregnancy. The long-term health risks to children associated with prenatal antibiotic exposure are uncertain.

Objective: To identify the association between prenatal antibiotics and adverse long-term health outcomes in children.

Methods: A systematic search was done to identify original studies investigating the association between prenatal antibiotic exposure and adverse long-term health outcomes in children. Studies were excluded if: (i) antibiotics were only given during delivery or (ii) the outcome was present before antibiotic exposure.

Results: We included 158 studies, reporting 23 outcomes in 21,943,763 children, in our analysis. For the following adverse health outcomes, there was a significant association with antibiotic exposure found in two or more studies: atopic dermatitis (OR 1.27, 95% CI 1.06-1.52, p=0.01), food allergies (OR 1.25, 95% CI 1.09-1.44, p<0.01), allergic rhinoconjunctivitis (OR 1.16, 95% CI 1.15-1.17, p<0.01), wheezing (OR 1.39, 95% CI 1.14-1.69, p<0.01), asthma (OR 1.36, 95% CI 1.24-1.50, p<0.01), obesity (OR 1.36, 95% CI 1.12-1.64, p<0.01), cerebral palsy (OR 1.25, 95% CI 1.10-1.43, p<0.01), epilepsy or febrile seizure (OR 1.16, 95% CI 1.08-1.24, p<0.01), and cancer (OR 1.13, 95% CI 1.01-1.26, p=0.04).

Conclusion: Although causality cannot be implied, these findings support antibiotic stewardship efforts to ensure judicious use of antibiotics during pregnancy to avoid potential long-term health risks.